NKTX - Nkarta Therapeutics

-

$undefined

N/A

(N/A)

Nkarta Therapeutics NasdaqGS:NKTX Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Location: 1150 Veterans Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.nkartatx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-63.13M

Cash

265.5M

Avg Qtr Burn

-25.2M

Short % of Float

14.32%

Insider Ownership

5.02%

Institutional Own.

92.03%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 1

Data readout

NKX019 (CAR NK cell therapy) Details
Systemic sclerosis, Idiopathic inflammatory myopathy / myositis, ANCA-Associated Vasculitis

Phase 1

Data readout

NKX019 (CAR NK cell therapy) Details
B-cell malignancies, Non-Hodgkin lymphoma, B-cell lymphoma

Phase 1

Data readout

NKX019 (CAR NK cell therapy) Details
Systemic lupus erythematosus, Autoimmune disease

Phase 1

Update

NKX101 (CAR-T targeting NKG2D) Details
Bone marrow disorder, Acute myeloid leukemia, Cancer, Myelodysplastic syndrome

Phase 1

Update

NKX019 Details
Myasthenia gravis

Phase 1

Initiation